Published Studies Related to Primaquine
Single dose primaquine for clearance of Plasmodium falciparum gametocytes in
children with uncomplicated malaria in Uganda: a randomised, controlled,
double-blind, dose-ranging trial. 
gametocyte clearance and for safety in P falciparum malaria... INTERPRETATION: We conclude that 0.4 mg/kg primaquine has similar gametocytocidal
Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. [2010.11.01]
BACKGROUND: Plasmodium vivax has a dormant hepatic stage, called the hypnozoite, which can cause relapse months after the initial attack. For 50 years, primaquine has been used as a hypnozoitocide to radically cure P. vivax infection, but major concerns remain regarding the side-effects of the drug and adherence to the 14-day regimen. This study examined the effectiveness of using the directly-observed therapy (DOT) method for the radical treatment of P. vivax malaria infection, to prevent reappearance of the parasite within the 90-day follow-up period. Other potential risk factors for the reappearance of P. vivax were also explored... CONCLUSIONS: Adherence to the 14-day primaquine regimen is important for the radical cure of P. vivax malaria infection. Implementation of DOT reduces the reappearance rate of the parasite, and may subsequently decrease P. vivax transmission in the area.
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. [2010.05]
The current interest in malaria elimination has led to a renewed interest in drugs that can be used for mass administration to minimize malaria transmission. Primaquine (PQ) is the only generally available drug with a strong activity against mature Plasmodium falciparum gametocytes, the parasite stage responsible for transmission...
A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. [2010.04]
Thai adult males (N = 85) with acute Plasmodium vivax malaria and normal glucose-6-phosphate dehydrogenase screening were randomized to receive 30 mg or 60 mg primaquine daily for 7 days (N = 43 and 42, respectively). The regimens were well tolerated and all patients recovered fully... A 1 week course of primaquine 60 mg daily is an effective treatment of vivax malaria in this region.
Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. [2010.02]
Plasmodium vivax is the second most important cause of morbidity in Ethiopia. There is, however, little information on P.
Clinical Trials Related to Primaquine
Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda [Recruiting]
The purpose of this study is to evaluate the safety and efficacy of lower doses of
primaquine compared to the dose recommended by the WHO for reducing P. falciparum
gametocytes in the infected human host to prevent transmission of falciparum malaria to the
anopheles mosquito vector.
Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects [Recruiting]
The observed changes of P. falciparum sensitivity to artemisinin lead to the intensification
of early detection as well as treatment monitoring in malaria infection. It is widely
accepted that the development of resistance can be delayed by the use of combination
therapy, especially combinations that include artemisinin derivatives (acts). As the
resistance problem is considered extremely serious; as a consequence, who has recommended
that all monotherapy for malaria should be stopped.
Current WHO guidelines recommend that the drug combination regimens using ACT with effective
partner medicines should be used to decrease the risk of development or spreading of
Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects [Recruiting]
This is a stardard pharmacokinetic interaction study. Subjects will be randomized to be
either group A or B. Group A. Subjects will have 3 hospitalizations to complete. Each
hospitalization will be about 12-24 hours depends on each regimen. Subjects in A group who
receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2
of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1
week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third
admission (visit 4) after 8 weeks wash out period.
Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of
chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of
primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week
wash out period in between.
Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria [Recruiting]
This randomized clinical trial will be conducted in subjects with uncomplicated Plasmodium
vivax malaria during November 2010 to March 2012. The aim of the study is to compare the
efficacy and safety of artesunate-amodiaquine plus primaquine (AS-AQ + PQ) and
dihydroartemisinin-piperaquine plus primaquine (DHP + PQ) in uncomplicated vivax malaria.
The significance of the study is to find alternative drug for treating patients with vivax
malaria in case the standard treatment is not available or become resistance. This study
will give thorough information about the efficacy and safety of 2 artemisinin-based
combination therapies (ACTs) in combination with primaquine. It will also inform the
Indonesian Ministry of Health on their suggested policies for radical cure of vivax malaria,
and provides evidence based treatment options for chloroquine resistant vivax malaria. This
study will also provide information about prevalence of glucose-6-phosphate dehydrogenase
(G6PD) deficiency and G6PD variants in North Sumatera population.
Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects [Recruiting]
The observed changes of P. falciparum sensitivity to artemisinin leads to the
intensification of early detection as well as treatment monitoring in malaria infection. It
is widely accepted that the development of resistance can be delayed by the use of
combination therapy, especially artemisinin-based combination therapies (ACTs). The
resistance problem is considered extremely serious and as the consequence WHO has
recommended that all monotherapy for malaria should be stopped Current WHO guideline
recommends the drug combination regimens using ACT with effective partner medicines to
decrease the risk of development or spreading of artemisinin resistance.
Dihydroartemisinin-piperaquine (DHA-PQP); the fixed-dose combination of Dihydroartemisinin
(DHA) and Piperaquine phosphate (PQP) is now one of the recommended drugs by WHO as the oral
treatment for uncomplicated P. falciparum. DHA-PQP composes of both blood schizonticidal
drugs, with different mechanism of action and different half-life to improve the therapeutic
efficacy and to prevent the development of drug resistance to the individual drug. Moreover,
it is beneficial for the mutual protection against resistance and long lasting protection
against new infection, due to long half-life of PQP.
Primaquine is an effective gametocytocidal for P. falciparum transmission prevention and as
tissue killing for the radical cure in Plasmodium vivax and Plasmodium ovale infection. It
will be given only in the presence of other antimalarials, so it is necessary that the data
of the potential drugs interaction of primaquine and DHA-PQP should be characterized. It is
inevitable that in the near future, Dihydroartemisinin-piperaquine (DHA-PQP) and primaquine
combination treatment becomes necessary. These drugs are metabolized by cytochrome P450
enzyme which potentially causes pharmacokinetic alteration, resulting in clinically
significant drug-drug interactions that can cause unanticipated adverse reactions or
therapeutic failures because of the suboptimal exposure of the parasite.
This study is planned to evaluate potential pharmacokinetic interaction of orally
administered primaquine (PQ) and dihydroartemisinin-piperaquine (DHA-PQP) in healthy adult
subjects. The results of these interaction studies are important in order to provide
clinical guidance for the optimum combination of primaquine and DHA-PQP treatment regimens
in malaria infections.